The world’s experiences of cell therapy in obstetrics and neurology will be debated by the medical class as of this Monday (01), in the Institute of Rede D’Or, in Botafogo, in the South Zone of Rio, and on Tuesday (02) , at the São Luiz Itaim Study Center in São Paulo. Cryopraxis® *, in partnership with Rede D’Or São Luiz, organizes the international event, which will be hosted by US specialists Dr. Paul Sanberg, consultant of Cryopraxis®, deputy dean of the University of South Florida and a reference and Evan Snyder, head of the cell therapy laboratory at the Sanford-Burnham Medical Research Institute.
The researchers will participate in the lectures with the theme Stem Cells in Perinatal Asphyxia, changing prognosis. “Perinatal anoxia is one of the leading causes of death for newborns worldwide and is responsible for severe and often irreversible sequelae. According to data from the Ministry of Health in 2011, about 2% of births in Brazil present some degree of asphyxia, explains the obstetrician and medical director of Cryopraxis®, Dr. Alberto d’Auria.
Neonatal anoxia is the absence or decrease of oxygenation in the brain that the baby has during childbirth. Pointed as one of the leading causes of neonatal death worldwide, anoxia is a serious problem that can affect the newborn, causing lesions in multiple organs.
According to the latest survey released by the Ministry of Health in 2011, although the infant mortality rate has decreased in recent years in Brazil (17 deaths per 1000 live births), the neonatal component (0 to 28 days of life) remained stable, accounting for 65% of the total. In this context, perinatal asphyxia is the third largest cause of death among newborns.
Hypothermia, a decrease in temperature, has now been used as a standard procedure for the treatment of perinatal asphyxia, but the number of newborn deaths is still high, and in survivors the occurrence of disabling sequelae greatly diminishes quality of life.
“Cell therapy is proposed as an alternative for the treatment of these lesions and other neurodegenerative diseases. Experimental studies, most of them developed by the invited researchers, demonstrate the potentiality of these cells. are indicative of the efficacy of treatment with the use of cord blood cells of the children themselves. Despite the advances observed, there is still a long way to go until this is a current practice in medicine, “explains the research coordinator of Cryopraxis® , Dr. Maria Helena Nicola.
Cryopraxis®, in partnership with the Antonio Pedro University Hospital of the Fluminense Federal University, is in the process of approving a clinical research protocol to evaluate the safety and efficacy of the cellular therapy procedure described above, thus effectively contributing to the advances of regenerative medicine in Brazil.
* Cryopraxis® is the largest Brazilian bank for the collection and storage of umbilical cord blood stem cells and has more than 30,000 units that are stored in liquid nitrogen tanks that control the temperature at -196 ° C. Established in 2001, the company became the leader and reference in the country in the area of Cellular Therapy. More information.
Source: Jornal do Brasil.